237 related articles for article (PubMed ID: 35779777)
21. Pharmacological bypass of NAD
Liu HW; Smith CB; Schmidt MS; Cambronne XA; Cohen MS; Migaud ME; Brenner C; Goodman RH
Proc Natl Acad Sci U S A; 2018 Oct; 115(42):10654-10659. PubMed ID: 30257945
[TBL] [Abstract][Full Text] [Related]
22. NMNAT2 supports vesicular glycolysis via NAD homeostasis to fuel fast axonal transport.
Yang S; Niou ZX; Enriquez A; LaMar J; Huang JY; Ling K; Jafar-Nejad P; Gilley J; Coleman MP; Tennessen JM; Rangaraju V; Lu HC
Mol Neurodegener; 2024 Jan; 19(1):13. PubMed ID: 38282024
[TBL] [Abstract][Full Text] [Related]
23. cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons.
Sasaki Y; Engber TM; Hughes RO; Figley MD; Wu T; Bosanac T; Devraj R; Milbrandt J; Krauss R; DiAntonio A
Exp Neurol; 2020 Jul; 329():113252. PubMed ID: 32087251
[TBL] [Abstract][Full Text] [Related]
24. Sarm1 haploinsufficiency or low expression levels after antisense oligonucleotides delay programmed axon degeneration.
Gould SA; Gilley J; Ling K; Jafar-Nejad P; Rigo F; Coleman M
Cell Rep; 2021 Dec; 37(11):110108. PubMed ID: 34910914
[TBL] [Abstract][Full Text] [Related]
25. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program.
Geisler S; Doan RA; Cheng GC; Cetinkaya-Fisgin A; Huang SX; Höke A; Milbrandt J; DiAntonio A
JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484833
[TBL] [Abstract][Full Text] [Related]
26. An Atypical SCF-like Ubiquitin Ligase Complex Promotes Wallerian Degeneration through Regulation of Axonal Nmnat2.
Yamagishi Y; Tessier-Lavigne M
Cell Rep; 2016 Oct; 17(3):774-782. PubMed ID: 27732853
[TBL] [Abstract][Full Text] [Related]
27. Axon Death Pathways Converge on Axundead to Promote Functional and Structural Axon Disassembly.
Neukomm LJ; Burdett TC; Seeds AM; Hampel S; Coutinho-Budd JC; Farley JE; Wong J; Karadeniz YB; Osterloh JM; Sheehan AE; Freeman MR
Neuron; 2017 Jul; 95(1):78-91.e5. PubMed ID: 28683272
[TBL] [Abstract][Full Text] [Related]
28. The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD
Essuman K; Summers DW; Sasaki Y; Mao X; DiAntonio A; Milbrandt J
Neuron; 2017 Mar; 93(6):1334-1343.e5. PubMed ID: 28334607
[TBL] [Abstract][Full Text] [Related]
29. Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide.
Sasaki Y; Vohra BP; Lund FE; Milbrandt J
J Neurosci; 2009 Apr; 29(17):5525-35. PubMed ID: 19403820
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of initiation and regulation of axonal degeneration with special reference to NMNATs and Sarm1.
Funakoshi M; Araki T
Neurosci Res; 2023 Dec; 197():3-8. PubMed ID: 34767875
[TBL] [Abstract][Full Text] [Related]
31. Nmnat2 delays axon degeneration in superior cervical ganglia dependent on its NAD synthesis activity.
Yan T; Feng Y; Zheng J; Ge X; Zhang Y; Wu D; Zhao J; Zhai Q
Neurochem Int; 2010 Jan; 56(1):101-6. PubMed ID: 19778564
[TBL] [Abstract][Full Text] [Related]
32. The SARM1 TIR domain produces glycocyclic ADPR molecules as minor products.
Garb J; Amitai G; Lu A; Ofir G; Brandis A; Mehlman T; Kranzusch PJ; Sorek R
PLoS One; 2024; 19(4):e0302251. PubMed ID: 38635746
[TBL] [Abstract][Full Text] [Related]
33. Wallerian degeneration: an emerging axon death pathway linking injury and disease.
Conforti L; Gilley J; Coleman MP
Nat Rev Neurosci; 2014 Jun; 15(6):394-409. PubMed ID: 24840802
[TBL] [Abstract][Full Text] [Related]
34. NMNAT2: An important metabolic enzyme affecting the disease progression.
Li W; Gao M; Hu C; Chen X; Zhou Y
Biomed Pharmacother; 2023 Feb; 158():114143. PubMed ID: 36528916
[TBL] [Abstract][Full Text] [Related]
35. Programmed axon degeneration: from mouse to mechanism to medicine.
Coleman MP; Höke A
Nat Rev Neurosci; 2020 Apr; 21(4):183-196. PubMed ID: 32152523
[TBL] [Abstract][Full Text] [Related]
36. An NAD+/NMN balancing act by SARM1 and NMNAT2 controls axonal degeneration.
Waller TJ; Collins CA
Neuron; 2021 Apr; 109(7):1067-1069. PubMed ID: 33831359
[TBL] [Abstract][Full Text] [Related]
37. SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation.
Summers DW; Gibson DA; DiAntonio A; Milbrandt J
Proc Natl Acad Sci U S A; 2016 Oct; 113(41):E6271-E6280. PubMed ID: 27671644
[TBL] [Abstract][Full Text] [Related]
38. Identification of the first noncompetitive SARM1 inhibitors.
Loring HS; Parelkar SS; Mondal S; Thompson PR
Bioorg Med Chem; 2020 Sep; 28(18):115644. PubMed ID: 32828421
[TBL] [Abstract][Full Text] [Related]
39. Axonal trafficking of NMNAT2 and its roles in axon growth and survival in vivo.
Milde S; Gilley J; Coleman MP
Bioarchitecture; 2013; 3(5):133-40. PubMed ID: 24284888
[TBL] [Abstract][Full Text] [Related]
40. Macrophage depletion blocks congenital SARM1-dependent neuropathy.
Dingwall CB; Strickland A; Yum SW; Yim AK; Zhu J; Wang PL; Yamada Y; Schmidt RE; Sasaki Y; Bloom AJ; DiAntonio A; Milbrandt J
J Clin Invest; 2022 Dec; 132(23):. PubMed ID: 36287209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
